Pakistan may consider use of dexamethasone for COVID-19 patients treatment

0
851

By Muhammad Luqman
Pakistan may consider the use of  dexamethasone to treat critical novel coronavirus patients, Special Assistant to Prime Minister on Health, Dr. Zafar Mirza said .
The number of patients in Pakistan has reached to the mark of 157738 with 3033 deaths.
Researchers in the UK announced a day earlier that dexamethasone — a cheap and widely available steroid drug — cuts the risk of death in severely ill coronavirus patients, and the World Health Organization (WHO) has hailed it as a “lifesaving breakthrough.”
Dr. Zafar Mirza said the country had ample supply of the drug and may include it in the standard treatment for COVID-19 patients on ventilators or in need of oxygen.
In a series of tweets, he said the WHO had responded positively to the new research and an expert committee in Pakistan will now consider making it part of the treatment plan.
“It is an old & cheap anti-inflammatory medicine (steroid) & we have multiple producers in Pakistan,” he said.

Mirza clarified that the medicine is only to be used for critically ill COVID-19 patients who are on ventilators or need oxygen.
“The medicine MUST NOT be used by mild to moderate patients; self-medication is strictly prohibited and can be dangerous as the medicine has many side-effects,” he warned.
On Tuesday, the WHO said dexamethasone had reduced mortality by about one third for patients on ventilators, and by about one fifth for patients requiring only oxygen, referring to preliminary findings of research conducted at Oxford University.
“This is the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support,” WHO chief Tedros Adhanom Ghebreyesus said.
“This is great news and I congratulate the Government of the UK, the University of Oxford, and the many hospitals and patients in the UK who have contributed to this lifesaving scientific breakthrough.”
Dexamethasone is a steroid that has been used since the 1960s to reduce inflammation in a range of conditions, including inflammatory disorders and certain cancers.
It has been listed on the WHO Model List of Essential Medicines since 1977 in multiple formulations, and is currently off-patent and affordably available in most countries, according to the global heath body.
Meanwhile, the demand for dexamethason has skyrocketed in Pakistan soon after its successful trial against COVID-19 in the United Kingdom.
” Its original price in Pakistan is 85 paisa. But now it is not available anywhere,” Muhammad Riaz, a Lahorite said.

LEAVE A REPLY

Please enter your comment!
Please enter your name here